Vaccinia virus vectors: new strategies for producing recombinant vaccines
- PMID: 2187593
- PMCID: PMC358149
- DOI: 10.1128/CMR.3.2.153
Vaccinia virus vectors: new strategies for producing recombinant vaccines
Abstract
The development and continued refinement of techniques for the efficient insertion and expression of heterologous DNA sequences from within the genomic context of infectious vaccinia virus recombinants are among the most promising current approaches towards effective immunoprophylaxis against a variety of protozoan, viral, and bacterial human pathogens. Because of its medical relevance, this area is the subject of intense research interest and has evolved rapidly during the past several years. This review (i) provides an updated overview of the technology that exists for assembling recombinant vaccinia virus strains, (ii) discusses the advantages and disadvantages of these approaches, (iii) outlines the areas of outgoing research directed towards overcoming the limitations of current techniques, and (iv) provides some insight (i.e., speculation) about probable future refinements in the use of vaccinia virus as a vector.
Similar articles
-
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. doi: 10.2174/1568005033481123. Curr Drug Targets Infect Disord. 2003. PMID: 14529359 Review.
-
Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice.Immunol Cell Biol. 1989 Oct;67 ( Pt 5):339-41. doi: 10.1038/icb.1989.49. Immunol Cell Biol. 1989. PMID: 2613281
-
Roles of vaccinia virus in the development of new vaccines.Vaccine. 1988 Apr;6(2):161-3. doi: 10.1016/s0264-410x(88)80021-5. Vaccine. 1988. PMID: 3291453 Review.
-
Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.Vaccine. 1990 Feb;8(1):17-21. doi: 10.1016/0264-410x(90)90171-h. Vaccine. 1990. PMID: 2316280
-
Present and future applications of vaccinia virus as a vector.Vet Parasitol. 1988 Sep;29(2-3):281-92. doi: 10.1016/0304-4017(88)90129-x. Vet Parasitol. 1988. PMID: 3059670 Review.
Cited by
-
Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).J Virol. 1995 Feb;69(2):1306-9. doi: 10.1128/JVI.69.2.1306-1309.1995. J Virol. 1995. PMID: 7815511 Free PMC article.
-
Assessing the generation of tissue resident memory T cells by vaccines.Nat Rev Immunol. 2023 Oct;23(10):655-665. doi: 10.1038/s41577-023-00853-1. Epub 2023 Mar 31. Nat Rev Immunol. 2023. PMID: 37002288 Free PMC article. Review.
-
Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.Cancers (Basel). 2018 Jul 10;10(7):231. doi: 10.3390/cancers10070231. Cancers (Basel). 2018. PMID: 29996551 Free PMC article.
-
Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.J Virol. 2002 May;76(9):4212-21. doi: 10.1128/jvi.76.9.4212-4221.2002. J Virol. 2002. PMID: 11932386 Free PMC article.
-
Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 Mycobacterium tuberculosis strains.PLoS One. 2025 May 14;20(5):e0322147. doi: 10.1371/journal.pone.0322147. eCollection 2025. PLoS One. 2025. PMID: 40367100 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous